Biocon Biologics Limited, an integrated global biopharmaceutical group and a subsidiary of Biocon Limited have been named under IAM (Intellectual Asset Management). IAM is a leader in international intellectual property publications, to Biocon...
Lupin, a global pharmaceutical company, is making a substantial move towards sustainability. The Science Based Targets initiative (SBTi) certified its greenhouse gas reduction plan, and includes Scope 1, Scope 2, and Scope 3 emissions...
Piramal Pharma Solutions NPS has reached a strong 55 for FY2025, signaling high customer loyalty and trust across its global operations. Announced today, the result highlights the company’s growing reputation as a reliable global CDMO and...
Roche has announced fresh momentum in clinical diagnostics with CE Mark approval for its new mass spectrometry reagent pack, a move that strengthens its position in mass spectrometry testing. The approval expands what is now the broadest IVD...
Aon plc, a leading global professional services firm, today released the India findings from its 2026 Global Medical Trend Rates Report. The report projects that employee medical plan costs in India will rise by 11.5 percent in 2026, down from...
In a promising leap for rare disease care, Recursion Pharmaceuticals revealed that its investigational drug REC-4881 delivered strong polyp reduction in patients with Familial Adenomatous Polyposis (FAP), a rare hereditary condition that...
Immutep has sealed a wide-reaching licensing pact with Dr Reddy’s Laboratories, giving the Indian drugmaker exclusive rights to develop and commercialize Eftilagimod Alfa (efti) across most global markets, except North America, Europe, Japan, and...
Biocon Limited has unveiled a major shift. It confirmed plans to fully integrate Biocon Biologics as a wholly owned subsidiary once regulatory and shareholder approvals are cleared. The move marks a pivotal moment for the company as it prepares...
Astrazeneca's presence at the 2025 ASH Annual Meeting is the largest sharpe in the history of ASH and represents Astrazeneca's continuing efforts to lead the way in haematology. The company's 65 abstracts represent an impressive milestone across...
Pharma company Corona Remedies, supported by private equity firm ChrysCapital, has set a price range of Rs 1,008-1,062 per share for its forthcoming Initial Public Offering (IPO), which values the firm at approximately Rs 6,500 crore
.jpg)
.jpg)
.jpg)
, CDSCO.jpg)